Stock Analiz

Biocryst Pharmaceuticals Inc. (BCRX) stock forecast and price target

Price $7.61 · data as of November 13, 2026

12-month price target

Average target$20.45
Upside / downside+168.8%
Analysts11
ConsensusBuy
Low $11.00Average $20.45High $32.00

Gold marker: average target · white marker: today’s price ($7.61)

Analyst ratings

Strong buy 2Buy 7Hold 2Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$0.86+36.3%$718M
Next fiscal year
ends December 31, 2027
$0.85−1.2%$736M
Next quarter
ends December 31, 2026
$0.10−52.0%$166M
Quarter after
ends March 31, 2027
$0.17+24.6%$167M

Consensus of the analysts covering Biocryst Pharmaceuticals, updated daily. In the last 30 days 1 estimates were raised and 0 lowered.

Our model vs. Wall Street

Analysts see 168.8% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Biocryst Pharmaceuticals’s intrinsic value about 64% below today’s market value, and it scores 1.6 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.

Frequently asked questions

What is the Biocryst Pharmaceuticals stock price target?

The average 12-month target from 11 analysts is $20.45, 168.8% above the current price of $7.61 Targets range from $11.00 to $32.00.

Is Biocryst Pharmaceuticals a buy according to analysts?

The consensus rating is “Buy” (2 strong buy, 7 buy, 2 hold). Ratings are opinions, not guarantees; this is not investment advice.

How much is Biocryst Pharmaceuticals expected to earn?

Analysts expect EPS of $0.86 for the fiscal year ending December 31, 2026 and $0.85 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.